# CD Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cd-diagnostics

- Industry: Healthcare
- Headquarters: US
- Website: www.cddiagnostics.com
- Total disclosed funding: $2.8M
- Latest round: Series A (Jun 18, 2012)
- Investors on record: 3

## About

CD Diagnostics develops advanced diagnostic solutions for joint pain, focusing on periprosthetic joint infection detection to improve patient outcomes in orthopedic care.CD Diagnostics specializes in diagnostic solutions for joint pain, with its headquarters located in the US. The company was acquired by Zimmer Holdings, Inc. in August 2016 for an undisclosed amount. The latest funding round was a Series A, securing USD 2.8 mn from BioStar Capital, Lankenau Institute for Medical Research, and Vital Venture Capital. The company has raised a total of USD 2.8 mn, with a current valuation of USD 33.031 mn.CD Diagnostics specializes in innovative diagnostic solutions for joint pain, with the Synovasure® test as its flagship product. This test aids in diagnosing periprosthetic joint infection (PJI) by detecting alpha-defensin, a biomarker associated with infection. The product line also includes the Alpha Defensin Lateral Flow Test Kit and the Alpha Defensin Control Kit, which serve a wide range of healthcare providers including hospitals and orthopedic clinics in the US and Europe.CD Diagnostics generates revenue through the sales of its diagnostic test kits, primarily the Synovasure® line. The company engages in direct sales to healthcare institutions, establishing long-term relationships with hospitals and orthopedic specialists. The revenue model is supported by the essential nature of its products in orthopedic diagnostics, ensuring ongoing demand in the healthcare sector, and the company may have partnerships with diagnostic laboratories to enhance distribution.Following its acquisition, CD Diagnostics aims to leverage recent funding to expand its product offerings and market reach. The company is focusing on launching new diagnostic products tailored for orthopedic applications by mid-2024. Additionally, CD Diagnostics plans to penetrate new geographical markets, targeting regions in Europe and Asia by late 2025, capitalizing on the growth opportunities within these markets.

## Funding rounds

- Series A, Jun 18, 2012, $2.8M — BioStar Capital, Vital Venture Capital, Lankenau Institute for Medical Research

## Investors

- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series A
- Vital Venture Capital (https://capitalatlas.ai/funds/vital-venture-capital) — Series A
- Lankenau Institute for Medical Research — Series A